Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers spot tell-tale signs of potentially fatal cardiac arrest in hypertrophic cardiomyopathy

General Research

In a study published in the Journal of the American College of Cardiology, a team of researchers from Radcliffe Department of Medicine borrowed a brain imaging technique to spot the tell-tale disarray in heart muscle fibres that could set off a potentially fatal heart rhythm in hypertrophic cardiomyopathy.

None

Hypertrophic cardiomyopathy is the leading cause of sudden cardiac death in young people (such as the unexpected near fatal cardiac arrest suffered by the-then 23 year old footballer Fabrice Muamba), but the microscopic heart muscle abnormalities behind these tragic events can only be picked up in a post-mortem.

Now, in a study published in the Journal of the American College of Cardiology, a team of RDM researchers have borrowed a brain imaging technique to spot the tell-tale disarray in heart muscle fibres that could set off a potentially fatal heart rhythm in hypertrophic cardiomyopathy.

This is the first time that these tell-tale signs can be spotted in living patients.

Read more (Radcliffe Department of Medicine website)

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

COVID winter plan: UK blueprint doesn’t go far enough – here’s a health expert’s alternative

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.